安体舒通能降低心衰住院率

A late-breaking clinical trial, known as the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone（醛固酮） Antagonist¹ (TOPCAT) trial, to be presented at the American Heart Association (AHA) Scientific Sessions, November 18, 2013, demonstrates that spironolactone（安体舒通） did not reduce the primary outcome of cardiovascular death, heart failure hospitalization, nor surviving a cardiac arrest in patients with heart failure and preserved ejection fraction (pump function). However, spironolactone did reduce the major burden faced by these patients-the risk of repeated hospitalizations for heart failure. The TOPCAT trial is the first randomized, double-blind trial to assess the effect of spironolactone on clinical outcomes in these patients with heart failure and preserved ejection fraction.   The trial enrolled² 3,445 participants from 270 medical centers in six countries. Participants were randomly³ assigned to receive either spironolactone (target dose of 30 milligrams/day) or matching placebo⁴, and were followed for an average of nearly 3.5 years. Moreover, participants were also treated for other co-existing conditions (e.g., diabetes⁵, high blood pressure, etc.).   According to the researchers, patients randomized to spironolactone were less likely to be hospitalized for heart failure compared to those on placebo. At the end of the study, 206 out of 1722 patients on spironolactone (12 percent) had been hospitalized for heart failure, compared to 245 of 1723 patients (14 percent) given placebo. There were no statistically⁶ significant differences between the groups in deaths or hospitalizations from any cause.   The TOPCAT trial also presented the opportunity to study cardiac structure and function in this population through an echocardiography sub-study in 935 patients, which demonstrated a high prevalence of abnormal cardiac structure in these patients. These results will be published simultaneously⁷ with the TOPCAT AHA presentation in the AHA journal, Circulation: Heart Failure.